Kewaunee Scientific Corporation announced its first-quarter fiscal year 2025 results, highlighting a solid performance driven by a strong backlog and consistent domestic manufacturing. While international sales faced challenges due to construction delays in India, the company remains optimistic about future growth.
Chewy, Inc. (CHWY) shares surged higher following Petco Health and Wellness Inc.’s (WOOF) second-quarter financial results. While Petco missed earnings targets, its sales met expectations, and a cryptic post by ‘Roaring Kitty’ on Reddit sparked meme stock excitement, boosting both Petco and Chewy shares.
Oxford Industries, Inc. (OXM) reported weaker-than-expected second-quarter financial results, missing both earnings and revenue estimates. The company attributed the shortfall to declining consumer sentiment, leading to a drop in full-price sales and increased demand for promotions. Oxford Industries lowered its third-quarter guidance and revised its full-year outlook.
The August Consumer Price Index (CPI) report delivered a mixed bag for those expecting swift and aggressive interest rate cuts by the Federal Reserve. While headline inflation slowed, core inflation remained stubbornly high, raising concerns about the Fed’s ability to ease monetary policy quickly. The market’s optimism for a 50-basis-point rate cut has cooled considerably, with the focus now shifting to the upcoming Producer Price Index (PPI) report for fresh inflation insights.
Kronos Worldwide (KRO) is poised for growth driven by increasing titanium dioxide (TiO2) demand and cost-cutting initiatives. The company’s earnings are expected to soar in 2024, making it an attractive investment option. This Zacks Rank #2 (Buy) stock stands out for its strong earnings growth prospects and favorable industry dynamics.
UnitedHealth Group has announced it will remove AbbVie’s blockbuster drug Humira from its preferred reimbursement lists starting in 2025, opting for lower-cost biosimilars instead. This move follows similar decisions by Cigna and CVS Health, marking a significant shift in the U.S. pharmaceutical market as health plans prioritize cost-cutting measures.
CVS Health Corporation (CVS) shares are experiencing a decline following the recent Trump-Harris debate, which has triggered uncertainty within the healthcare sector. The decline may be linked to the potential impact of the debate on healthcare policy and the mixed sentiment among traders regarding CVS’s future prospects.
Ziel’s innovative radiofrequency (RF) technology offers a non-ionizing solution to microbial contamination in cannabis, preserving product quality and ensuring compliance with organic certification standards. This cutting-edge technology provides a sustainable and efficient alternative to traditional methods like X-rays, offering significant cost savings and improved product safety.
Robinhood is aggressively pushing into the crypto market, targeting millennial investors and significantly increasing its revenue. Their strategy involves expanding crypto services, acquisitions, and potential new offerings like crypto lending. This focus has led to a significant increase in revenue and a growing market cap, with millennials driving much of this growth.
Pharmaceutical giant Johnson & Johnson is facing a lawsuit for allegedly using copyrighted music without permission in numerous online videos. Associated Production Music (APM) claims Johnson & Johnson used nearly 80 videos featuring unlicensed tracks, potentially facing significant financial penalties if found guilty.
